

Prolonged Maternal Shedding and Maternal-fetal Transmission of Measles Virus

Caroline Charlier, Julia Dina, François Freymuth, Astrid Vabret, Olivier Lortholary, Denise Antona, Marc Lecuit

▶ To cite this version:

Caroline Charlier, Julia Dina, François Freymuth, Astrid Vabret, Olivier Lortholary, et al.. Prolonged Maternal Shedding and Maternal-fetal Transmission of Measles Virus. Clinical Infectious Diseases, 2020, pp.ciaa915. 10.1093/cid/ciaa915. pasteur-02979562

HAL Id: pasteur-02979562 https://pasteur.hal.science/pasteur-02979562v1

Submitted on 27 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Prolonged maternal shedding and maternal-fetal transmission of measles virus

Caroline Charlier^{1,2,3}, Julia Dina^{4,5}, François Freymuth^{4,5}, Astrid Vabret^{4,5},

Olivier Lortholary³, Denise Antona⁶ and Marc Lecuit^{1,2,3}

¹ Institut Pasteur, Biology of Infection Unit, Paris, France

² Inserm U1117, Paris, France

³ Université de Paris, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de

Paris, Institut Imagine, Paris, France

⁴ Normandie University, UNICAEN, GRAM EA2656, CHU de Caen, Virology Department, Caen, France

⁵ National Reference Center for Measles Mumps and Rubella, CHU de Caen, 14000, France

⁶ Santé Publique France, Saint Maurice, France

Key words: measles, placenta, pregnancy, congenital infection

Running title: measles in pregnant women and newborns

Word count: 1535

Key points: Measles in pregnant women is associated with prolonged detection of viral RNA in saliva and blood. Asymptomatic maternal-fetal transmission and congenital infection can occur.

Correspondence to:

Caroline Charlier, caroline.charlier@pasteur.fr Marc Lecuit, marc.lecuit@pasteur.fr Biology of Infection Unit, Institut Pasteur, Inserm U1117, 28 rue du Dr Roux, 75015 Paris, France Phone: +33 1 40 61 34 20 Fax: +33 1 40 61 34 21

Abstract

Prolonged measles virus detection in maternal saliva and blood was evidenced in 6 pregnant women. Maternal-fetal transmission was evidenced in 2/4 infants who were asymptomatic at birth, 21-24 weeks after maternal infection. Whereas peripartum congenital measles is severe, asymptomatic measles virus vertical transmission can occur earlier in pregnancy.

Introduction

Measles is re-emerging, despite the availability of a safe and effective vaccine. This is due to the highly contagious nature of measles virus, requiring vaccine coverage > 93% to achieve herd immunity. Suboptimal vaccination has led to a massive resurgence and non-immune adults now account for up to 50% of cases. Measles, that was exceptionally rare in pregnant women, is increasingly reported [1-3]. Available data in the pregnant population mainly focus on measles severity [4, 5]. 10-40% of infected pregnant women develop pneumonia [2, 6]. Mortality (3-15%) is at least twice higher than in non-pregnant patients [3, 5, 6], depending on access to supportive care and comorbidities like HIV infection [7, 8]. Fetal losses or premature deliveries are also reported in 20-60% [4, 5, 9], and maternal viremia within ten days before delivery may lead to congenital measles, a severe condition that warrants administration of immunoglobulins [10]. Data on viral shedding in pregnant women and maternal-fetal transmission at earlier stages are lacking. We retrospectively studied pregnant women and their infants with measles which had been confirmed by serological and molecular methods, to study the duration of viral shedding and maternal-fetal transmission.

Patients and methods

Data collection – Measles is a reportable disease in France. We contacted each physician that reported a case of measles during pregnancy from 05/2012 to 04/2015 to Santé Publique France. Patients with available information were included after informed consent. Physicians at the study site were interviewed to collect medical and follow-up data. Mothers were re-contacted \geq 3 years after onset to evaluate infants' outcome. Given its retrospective nature, this study did not require Institutional Review Board approval according to French law, as assessed by our ethical committee (Necker-Enfants Malades Hospital Ethical Committee).

Case definition – Cases were defined as pregnant women with measles, confirmed by measles IgM and IgG in saliva, and/or significant rise in measles serum IgG between acute and convalescent titers, and/or viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR) in saliva.

Characterization of viral isolates – Available saliva, whole blood, cord blood, serum and/or placenta samples from cases and infants were sent to the French National Reference Centre (NRC) for measles. RT-PCR were performed: total RNAs were extracted (EZ1 Advanced XL Qiagen EZ1 DSP Virus kit 48), followed by two rounds of RT-PCR and semi-nested PCR [11]. A highly conserved region located on the N gene of MV genome, coding the carboxy-terminal 150 amino acids of the nucleoprotein, was amplified. The test included primers for RNAse P housekeeping gene. Sequences were analyzed on Sequencing Analysis6 software (Applied Biosystems, USA). Genotyping could be carried out when the cycle threshold (Ct) was < 30Ct. Phylogenetic trees were generated based on Kimura 2-parameter model, the Neighbor-Joining algorithm and 450 nucleotides of the measles virus nucleoprotein using MEGA6 software, using the most recent reference sequences and all named strains of genotype D4 (MN922136-MN922137).

Immunological assays – Specific IgM and IgG antibodies detection in saliva and/or blood samples were performed by capture enzyme immunoassay (Microimmune Clin-Tech kits).

Results

Study population – Six patients were included from 1,017 notified cases, including 218 in women of childbearing age (15-45 years) (features are detailed in **Table 1**). One patient had received a single-dose measles vaccination. Others (5/6) were unvaccinated.

Clinical features – Measles occurred at a median of 19 weeks of gestation (WG) (range, 6-33). All mothers reported rash and fever (median temperature 39°C). Lower respiratory tract involvement (bronchiolitis or interstitial pneumonia) was reported in three (3/6). Four patients required hospitalization in the obstetrical (3/6) or infectious diseases ward (1/6). One patient reported fetal loss attributed to measles at 6 WG (case#6). Others experienced uneventful pregnancy and delivery. All infants were reported healthy at birth, except for one born at 36 WG (16 weeks after maternal infection) with mild uncomplicated jaundice (case #2). As all mothers experienced measles weeks before delivery, no infant was prescribed immunoglobulins. Follow-up data at 3-6-year were available for four children: all exhibited normal growth without reported neurodevelopmental defect, except for one with unexplained tooth enamel damage (case #1).

Maternal biological features – Four maternal cases were identified by positive salivary RT-PCR (cases #1-4). Two were diagnosed by salivary measles IgM (cases #5-6). One patient (case #2) also had positive RT-PCR on whole blood collected 21 days after rash onset; all other maternal sera were negative for measles virus RNA 7, 28 and 40 days after rash onset. Four cases had sequential blood and saliva samples. All exhibited measles-specific IgM in saliva samples collected 1-28 days after onset, with IgG seroconversion before D15 in one and between D5 and 16 in another. Measles virus RNA was constantly detected in saliva samples collected from day 1-28 after rash onset, including in the 4 samples collected from D15-D28. Median time interval between rash onset and last positive saliva sample was 18 days (range 15-28).

Infant biological features – Four neonates had samples at birth : saliva in three, of whom two also had cord blood samples; and cord blood and serum in one. Two infants had strong evidence for maternal-fetal viral transmission: one had viral RNA detected in saliva (21 weeks after maternal infection onset, case#4); another had anti-measles IgM detected in saliva (case #3). Another had anti-measles IgM detected in cord blood but not in serum at birth, suggesting possible contamination with maternal blood (case #2), the last had anti-measles IgM and IgG in the cord blood but no serum collected to decipher whether IgM reflected fetal infection or contamination with maternal blood (case #1). Measles RT-PCR test was positive in 2/2 placentas collected 6-8 weeks after maternal infection onset, with for case #1 a concomitant negative RT-PCR in maternal blood.

Discussion

Here, we analyzed the clinical and biological features of six pregnant women with measles. Maternal clinical presentation is in line with previous European and North American reports [3], and less severe than recently reported from Namibia, where prevalence of HIV infection is 15% [8]. Early fetal loss was reported in one case (17%); all mothers recovered, despite frequent respiratory involvement (33%) and need for hospitalization (67%).

No patient was adequately vaccinated against measles and rubella (n=6), and among multiparous women, none received the catch-up vaccination recommended in France in the post-partum period.

Viral shedding appears prolonged in pregnant women: measles RNA was constantly evidenced in maternal saliva samples collected within 15 days following rash onset, and could be evidenced up to 28 days after onset. In contrast, Riddell *et al.* who analyzed by RT-PCR in saliva samples of 74 adults with measles evidenced viral RNA in only 20% 14 days after onset, and all samples were negative \geq 20 days after onset [12]. Prolonged viremia in pregnant women had been suggested before by Forthal *et al.*, who evidenced persisting viremia in 4/6 adults 6 days after onset, of which 2 pregnant women [13]. In our series, the only patient tested had detectable viremia 21 days after onset. Although detection of viral RNA in saliva or blood does not systematically translate into prolonged contagiousness, our observations suggest that longer droplet precautions is likely required in pregnant women, who frequently seek to the obstetrical ward and may contaminate other non-immune pregnant women [6, 8].

Data regarding measles placental infection are limited to the single observation of viral particles in syncytiotrophoblasts in one placenta [14]. Here, we confirm the presence of viral RNA in 2/2 tested placentas whereas maternal blood was negative in one case, arguing for prolonged fetal-placental measles virus infection after resolution of maternal infection.

We also found evidence for maternal-fetal transmission in 2/4 cases with no symptoms in neonates, although we could not compare viral genome from mother and child. One neonate had measles IgM in the saliva, reflecting fetal/neonatal antibodies toward measles virus; another had viral RNA in the saliva 21 weeks after maternal infection. Congenital measles infection usually manifests as a severe infection occurring as a consequence of maternal viremia in the last ten days of pregnancy. This condition was associated with up to 30% mortality before the immunoglobulins' era, and is associated with an increased risk of subacute sclerosing panencephalitis below 2-years of age [15]. Here, infants with evidence for congenital infection were asymptomatic. None received immunoglobulins, and all reported uneventful evolution at the age of 3 and 6 years, except for one with enamel damages, which have not been ever reported in congenital measles, and are likely not attributable to this condition. Our data suggest that the concept of congenital measles virus vertical transmission should be broadened, and include asymptomatic infections after maternal infection are at risk of long-term neurological complication is unknown. This warrants measles virus detection in saliva

and blood serological assay in neonates born form mother who experienced measles during pregnancy, and their long-term neurological follow-up. The main limitation of this study is its retrospective nature. In the context of ongoing measles epidemics [1, 16], with vaccine coverage below 90% in most European countries [17], the evidence of prolonged measles virus shedding in pregnant women and the possibility of asymptomatic congenital infections with neonatal viral shedding at birth highlight a so far unsuspected transmission risk, which should be further studied to better define its magnitude and consequences.

Conflict of interest : none.

References

- Antona D, Levy-Bruhl D, Baudon C, et al. Measles elimination efforts and 2008-2011 outbreak, France. Emerg Infect Dis 2013; 19(3): 357-64.
- Ogbuanu IU, Zeko S, Chu SY, et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. Clin Infect Dis 2014; 58(8): 1086-92.
- Eberhart-Phillips JE, Frederick PD, Baron RC, Mascola L. Measles in pregnancy: a descriptive study of 58 cases. Obstet Gynecol 1993; 82(5): 797-801.
- Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992; 14(1): 217-26.
- 5. Nouvat J. Rougeole et Grossesse. Bordeaux: Faculté de Médecine, 1904.
- Ali ME, Albar HM. Measles in pregnancy: maternal morbidity and perinatal outcome. Int J Gynaecol Obstet 1997; 59(2): 109-13.
- Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nat Rev Dis Primers 2016;
 2: 16049.
- Ogbuanu IU, Zeko S, Chu SY, et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. Clin Infect Dis 2014; 58(8): 1086-92.
- Dao B, Koalaga AP, Ki Zerbo G, Bambara M, Bazie AJ. [Measles and pregnancy. Apropos of 16 cases in Burkina Faso]. J Gynecol Obstet Biol Reprod (Paris) 1997; 26(6): 606-9.
- Charlier C, Hourrier S, Leruez-Ville M, et al. Polyvalent immunoglobulins in neonates after perinatal exposure to measles: Benefits and long-term tolerance of immunoglobulins. J Infect 2015; 71(1): 131-4.

- 11. Hummel KB, Lowe L, Bellini WJ, Rota PA. Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens. J Virol Methods **2006**; 132(1-2): 166-73.
- 12. Riddell MA, Chibo D, Kelly HA, Catton MG, Birch CJ. Investigation of optimal specimen type and sampling time for detection of measles virus RNA during a measles epidemic. J Clin Microbiol **2001**; 39(1): 375-6.
- Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. Degree and length of viremia in adults with measles.
 J Infect Dis 1992; 166(2): 421-4.
- Ohyama M, Fukui T, Tanaka Y, et al. Measles virus infection in the placenta of monozygotic twins. Mod Pathol 2001; 14(12): 1300-3.
- Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007; 36(6): 1334-48.
- Andrianou XD, Del Manso M, Bella A, et al. Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, September 2016 to July 2018. Euro Surveill 2019; 24(17).
- Antona D, Morel P, Jacquot C, et al. Measles and rubella seroprevalence in a population of young adult blood donors, France 2013. Epidemiol Infect 2019; 147: e109.

Table 1. Main features of the 6 patients included in the cohort. D denotes days after maternal rash onset. Ct denotes Cycle threshold. RT-PCR denotes reverse transcriptase- polymerase chain reaction.

Demographical features Past history	Term Gestity, Parity	Clinical and virologic features ¹	Delivery	Infant features ³
38-yr No past medical history No prior measles vaccination	33-WG G2P1	Fever, rash, diarrhea, blurred vision, interstitial pneumonia ² . 7-d hospitalization and amoxicillin treatment	Uneventful 41WG	Normal examination at birth Normal neurodevelopmental features at 6-yrs follow-up, but severe unexplained tooth enamel damage
		Whole blood RT-PCR negative at D7 and D193 Saliva RT-PCR positive at D7 (Ct 33.4) and D19 (Ct 34.2)		Placenta RT-PCR positive (Ct 26,5) ⁵ Cord blood and saliva RT-PCR negative IgG and IgM positive in the cord blood
		IgG and IgM positive in the saliva at D7 and D19		IgG avidity in the cord: 19% (29% in a paired maternal sample).
Case #2 25-yr No past medical history Single dose measles vaccination	20-WG G1P0	Fever, rash, bronchiolitis	Uneventful 36WG	Moderate unexplained prematurity Mild neonatal jaundice attributed to prematurity Normal neurodevelopmental features at 6-yrs
		Saliva RT-PCR positive at D1 (Ct 19.1) ⁴ and D15 (Ct		Cord blood RT-PCR negative
		IgM positive in the saliva at D1 and D15 IgG negative in the saliva at D1 and positive at D15		IgG positive in the cord blood and l serum (avidity 52%); IgM positive in the cord blood, negative in the serum
Case #3 23-yr IgA-related vasculitis in childhood	14-WG G1P0	Fever, rash, conjunctivitis	Uneventful 40WG	Normal examination at birth Normal neurodevelopmental features at 3-yrs
		Saliva RT-PCR positive at D28 (Ct 37.4)		IgM positive in the saliva
Case#4 34-yr No past medical history No prior measles vaccination	19-WG G3P1	Fever, rash, interstitial pneumonia ¹ 3-d hospitalization	Uneventful 40WG	Normal examination at birth Normal neurodevelopmental features at 6-yrs
		Saliva RT-PCR positive at D5 (Ct 22.6)⁵ and D17 (Ct 24.2) IgM positive in the saliva at D5 and D17 IgG negative in the saliva at D5 and positive at D17		Placenta RT-PCR positive (Ct 37.3) Saliva RT-PCR positive (Ct 38.4) (cord blood negative) IgG positive in the cord blood (avidity 43%)
Case #5 29-vr	26-WG	Fever, rash, liver cytolysis	Uneventful	IgM negative in the cord blood Normal examination at birth
No past medical history No prior measles	G1P0	1-d hospitalization Whole blood RT-PCR negative at D40	40WG	Normal neurodevelopmental features at 6-yrs
26-yr No past medical history No prior measles	6-WG G1P0	Fever, rash 3-d hospitalization IgM positive un the saliva at D1		Early fetal loss
	Past history 38-yr No past medical history No prior measles vaccination 25-yr No past medical history Single dose measles vaccination 23-yr IgA-related vasculitis in childhood 34-yr No past medical history No prior measles vaccination 29-yr No past medical history No prior measles vaccination 29-yr No past medical history No prior measles vaccination 29-yr No past medical history No prior measles vaccination 26-yr No past medical history	Past historyGestity, Parity38-yr33-WGNo past medical history No prior measles vaccinationG2P125-yr20-WGNo past medical history Single dose measles vaccinationG1P023-yr14-WGIgA-related vasculitis in childhood14-WG34-yr19-WGNo past medical history No prior measles vaccination19-WG29-yr26-WGNo past medical history No prior measles vaccinationG1P029-yr26-WGNo past medical history No prior measles vaccinationG1P029-yr26-WGNo past medical history No prior measles vaccinationG1P026-yr6-WGNo past medical history No prior measles vaccinationG1P0	Past historyGestity, Parity38-yr33-WG G2P1Fever, rash, diarrhea, blurred vision, interstitial pneumonia2.No past medical history vaccinationG2P1Fever, rash, diarrhea, blurred vision, interstitial pneumonia2.No prior measles vaccinationG2P1Fever, rash, diarrhea, blurred vision, interstitial pneumonia2.25-yr No past medical history Single dose measles vaccination20-WG G1P0Fever, rash, bronchiolitis25-yr Single dose measles vaccination20-WG G1P0Fever, rash, bronchiolitis25-yr Single dose measles vaccination20-WG G1P0Fever, rash, bronchiolitis23-yr IgA-related vasculitis in childhood14-WG G1P0Fever, rash, conjunctivitis23-yr IgA-related vasculitis in childhood14-WG G1P0Fever, rash, conjunctivitis34-yr No past medical history No prior measles vaccination19-WG G1P0Fever, rash, interstitial pneumonia1 3-d hospitalization29-yr No past medical history No prior measles vaccination26-WG G1P0Fever, rash, liver cytolysis 1-d hospitalization29-yr No past medical history No prior measles vaccination26-WG G1P0Fever, rash, liver cytolysis 1-d hospitalization29-yr No past medical history No prior measles vaccination6-WG G1P0Fever, rash, liver cytolysis 1-d hospitalization29-yr No prior measles vaccination6-WG G1P0Fever, rash 3-d hospitalization29-yr No prior measles No prior measles6-WG G1P0Fever, rash 3-d hos	Past historyGestity, Parity38-yr33-WGFever, rash, diarrhea, blurred vision, interstitial pneumonia ² .Uneventful 41WGNo past medical history vaccination221Fever, rash, diarrhea, blurred vision, interstitial pneumonia ² .Uneventful 41WG25-yrWhole blood RT-PCR pegative at D7 and D193 Saliva RT-PCR positive at D7 (Ct 33.4) and D19 (Ct 34.2) IgG and IgM positive in the saliva at D7 and D19Uneventful 36WG25-yr20-WG G1P0Fever, rash, bronchiolitis Uneventful 30.5Uneventful 36WG25-yr20-WG G1P0Fever, rash, bronchiolitis Uneventful 30.5Uneventful 36WG23-yr tigle dose measles vaccination14-WG G1P0Fever, rash, conjunctivitis Uneventful 40WGUneventful 40WG23-yr tigle dose measles vaccination14-WG G1P0Fever, rash, conjunctivitis Uneventful 40WGUneventful 40WG34-yr No past medical history No prior measles vaccination19-WG G3P1Fever, rash, interstitial pneumonia ¹ 3-d hospitalizationUneventful 40WG34-yr No past medical history No prior measles vaccination26-WG G1P0Fever, rash, liver cytolysis G1P0Uneventful 40WG29-yr No past medical history No prior measles vaccination26-WG G1P0Fever, rash, liver cytolysis G1P0Uneventful 40WG29-yr No past medical history No prior measles No past medical history No prior measles26-WG G1P0Fever, rash, liver cytolysis G1P0Uneventful 40WG29-yr No past medica

¹ The Cycle threshold (Ct) value is inversely correlated with the amount of PCR product in the reaction: the lower the Ct value, the more PCR product is present. ² Pneumonias were radiologically confirmed. No virologic respiratory sample was performed.

³ Long-term follow-ups were evaluated through maternal interview that compiled the following information: grade level, past or concomitant follow-up for any disorder including attention/concentration behavioral, language disorders, anxiety, depression, motor or sensorial deficiency).

⁴ MeaNS ID: 144212, WHO sequence name: MVs/Labruguiere.FRA/18.12, with an exact match to MVs/Marmande.FRA/43.11/2. Genotype D4.

⁵ MeaNS ID: 144213, WHO sequence name: MVs/Eaubonne.FRA/19.12, with an exact match to MVs/Manchester.GBR/10.09. Genotype D4.